PRE-AUTHORIZATION FORM FOR PROMETHEUS[®] TPMT Genetics

This form is provided for your convenience; however, your patient's health care plan may require their own form.

ATTN: Pre-Authorization Department

DATE:			
Insurance Company:		Fax #	:
	PLEASE PR		
PHYSICIAN INFORMATION			
Account Name			
Physician Name	NPI/License #		
Address		City	StateZip
Medical Group		Group/Provide	r #
Phone #	Extension:	Best time to Ca	II
Contact	Fax # Email		
Primary Care Physician Name	Phone #:		
PATIENT INFORMATION			
Patient Name		_Patient DOB	_//Sex () M () F
Social Security #			
Address		City	StateZip
Primary Care Physician		Phone #	
Patient History:			
Diagnosis Code(s),			
		-	
INSURANCE INFORMATION			
INSURANCE INFORMATION			
INSURANCE INFORMATION Insurance Carrier Policy holder	DOB	//	Relationship to insured
INSURANCE INFORMATION	DOB	//	Relationship to insured

PRE-AUTHORIZATION FORM FOR PROMETHEUS[®] TPMT Genetics

This fax is to respectfully request an authorization for laboratory services at Pro-	metheus Lat	oorato	ories Inc	
in San Diego, CA for my patient	_DOB:	/	1	÷
I consider this test a medically necessary step in the diagnosis and treatment of	my patient.	Pleas	se appro	ve full
coverage for my patient. I look forward to receiving your response within two bus	siness days.	. Plea	se conta	act my
office with additional questions.				

Sincerely,

Х

ATTACHMENTS:

- () Letter of Medical Necessity
- () Chart Notes
- () Other: _____

CPT CODES (as applied by Prometheus)	PROMETHEUS TPMT Genetics
81335	TPMT Genetics (genotype)

Laboratory Description

Prometheus Laboratories Inc. (**Tax ID#** 33-0685754 **NPI#** 1073642641) is located in San Diego, CA and licensed in several states including New York and California. This test was developed and its performance characteristics determined by Prometheus Laboratories Inc. It has not been cleared or approved by the U.S. Food and Drug Administration. Prometheus Laboratories Inc. is a CAP-accredited CLIA laboratory.

Test Description

PROMETHEUS TPMT Genetics classifies patients as one of three genotypes: homozygous normal (wild type), heterozygous or homozygous mutant. Because each patient metabolizes thiopurines differently, the efficacy and toxicity of thiopurines can vary widely from patient to patient. Knowledge of the TPMT genotype may; reduce time to response, allow physicians to individualize dosing, identify patients in whom thiopurine therapy should be avoided and help reduce the risk of leukopenia.

PROMETHEUS TPMT Genetics is performed only at Prometheus Laboratories Inc.

It is recommended that you provide all specific, applicable diagnostic codes. Specific diagnostic codes assist the payer in coverage determination.

DX18007 03/18